Sign in / Join Now
ETFs & Funds
Abraxane data on panc
. SPARC hypothesis controversial. Abrax does not improve
, which is usually SPARC+.
Perhaps destroying SPARC/stroma promotes metastasis - allows for easier malignant cell escape. Abrax should have worked better in breast
Off topic: Did
get halted today? I can't wait to see the Study 301 results!! (the non-carrier one) Or was it the Study 300?
Add a reply...
Latest StockTalks »
people get CELG breaking news and analysis by email alert.
Get email alerts on CELG »
Get latest price
From other sites
Commit To Purchase Celgene Corp. At $55, Earn 3.4% Using Options
at Nasdaq.com (Fri, 11:46AM)
The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen
at Zacks.com (Thu, 9:30AM)
Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug
at Zacks.com (Wed, 3:36PM)
Celgene (CELG), Jounce Strike Immunotherapy Collaboration
at Zacks.com (Wed, 9:43AM)
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
at Zacks.com (Mon, 6:45PM)